84. Sarcoidosis Clinical trials / Disease details

Clinical trials : 149 / Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167

8 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02523092 (ClinicalTrials.gov)	October 2020	10/8/2015	Use of CXCL9 as a Biomarker of Acthar Efficacy	Use of CXCL9 as a Biomarker of Acthar Efficacy	Sarcoidosis	Drug: Acthar gel	University of California, San Francisco	Mallinckrodt	Not yet recruiting	18 Years	65 Years	All	14	Phase 4	United States
2	NCT02920710 (ClinicalTrials.gov)	February 1, 2019	29/9/2016	ACTHAR Therapy for Central Nervous System Sarcoidosis	ACTHAR Therapy for Central Nervous System Sarcoidosis	Sarcoidosis	Drug: Repository Corticotropin Injection	The Cleveland Clinic	Mallinckrodt	Withdrawn	N/A	N/A	All	0	Phase 4	United States
3	NCT03320070 (ClinicalTrials.gov)	February 21, 2018	20/10/2017	Acthar Gel in Participants With Pulmonary Sarcoidosis	A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis	Sarcoidosis, Pulmonary	Drug: Acthar Gel;Drug: Placebo	Mallinckrodt	NULL	Completed	18 Years	90 Years	All	55	Phase 4	United States
4	NCT02725177 (ClinicalTrials.gov)	July 2016	11/3/2016	Ocular Sarcoidosis Open Label Trial of ACTHAR Gel	Ocular Sarcoidosis Open Label Trial of ACTHAR Gel	Ocular Sarcoidosis;Panuveitis;Anterior Uveitis	Drug: Repository Corticotropin Injection;Drug: Repository Corticotropin Injection -Treatment Extension	The Cleveland Clinic	Mallinckrodt	Recruiting	18 Years	99 Years	All	20	N/A	United States
5	NCT02298491 (ClinicalTrials.gov)	May 2016	14/11/2014	CNS Sarcoidosis and Acthar Gel	Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel	CNS Sarcoidosis	Drug: H.P. Acthar Gel	University of Maryland, Baltimore	Mallinckrodt	Completed	N/A	N/A	All	4	Phase 4	United States
6	NCT02348905 (ClinicalTrials.gov)	March 2015	20/6/2014	ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial	ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial	Sarcoidosis;Cutaneous Sarcoidosis	Drug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly.	Albany Medical College	NULL	Not yet recruiting	18 Years	N/A	Both	10	Phase 2/Phase 3	United States
7	NCT02155803 (ClinicalTrials.gov)	February 2015	30/5/2014	ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study	ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study	Sarcoidosis;Hypercalcemia Due to Sarcoidosis	Drug: ACTHAR Gel (adrenocorticotropic hormone)	Albany Medical College	NULL	Not yet recruiting	18 Years	N/A	Both	10	Phase 2/Phase 3	United States
8	NCT02188017 (ClinicalTrials.gov)	June 2014	24/4/2014	Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)	ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)	Sarcoidosis;Pulmonary Sarcoidosis	Drug: Acthar gel	University of Cincinnati	Mallinckrodt	Recruiting	18 Years	90 Years	Both	20	Phase 4	United States